GHP July 2017

10 GHP / July 2017 , United Biomedical’s (UBI) product pipeline is filled with their new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s disease (AD), AIDS, autoimmune diseases and allergy, along with a portfolio of animal health diseases. Chairperson & CSO, Chang Yi Wang reveals more about the firm’s products and platform technologies in her own words. “These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. “Our platform technologies, from molecular and cellular engineering of high yield antibody and protein production of specific products by CHO cells, are also being used to develop a line of biosimilar and biobetter versions of widely used protein and antibody drugs whose patents are about to expire. “UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialised synthetic peptide vaccine. A second designer peptdie vaccine for immunocastration has gained product regulatory approvals as first class new biologics in Taiwan, Mexico and Brazil with many more to follow.” 1612GH13 A Voyage of Discovery United Biomedical, Inc. (UBI) is a privately heldmultinational biopharmaceutical company dedicated to the discovery, development and commercialisation of immunotherapeutics and vaccines for chronic and infectious diseases. Included in ourHealthcare &Pharma Leading Experts series, we enjoyed a short interviewwith Chairperson&CSO, Chang YiWang, Ph.D. to discovermore about the company’s excitingwork around health research. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development, Chang goes on to say, before outlining her own important role in the company, as the interview concludes. “My own role in the company is co-founder of UBI and a chairperson of the board of directors since 1998. I am also the chairperson and CEO of UBI-Asia. I am the principal inventor of at least 80 of UBI’s issued patents and patent applications. Under my direction, UBITh platform technology was developed. I have published more than 120 peer reviewed scientific papers and I have been invited to give plenary lectures in the areas of immunology, vaccination, immunotherapeutics and infectious diseases. “I also serve on the US NIH scientific review committee for the ‘Cooperative Research Partnerships for BioDefense’ funding programme and the SBIR Immunobiology and Allergy funding programme. In 2007, I was delighted to receive the Inventor of the Year Award from the New York Intellectual Property Law Association (NYPLA). “From 1981 to 1985, I was a principal investigator and head of the laboratory of molecular immunology at the Memorial Sloan-Kettering Cancer Center in New York and a faculty member of the Department of Immunology, Sloan-Kettering Division, Cornell University Medical School. I received my B.S. degree in Chemistry from National Taiwan University and a Ph.D. degree in Immunology and Biochemistry from The Rockefeller University, New York.” Company: United Biomedical, Inc. Name: Chang Yi Wang, Ph.D. Chairperson, CSO Email: [email protected] Web Address: www.unitedbiomedical.com Address: Corporate Headquarters 25 Davids Drive. Hauppauge, NY 11788 USA Telephone: +1 631 273 2828